Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Abbott, Ypsomed and CamDiab team up to offer hybrid closed loop with more affordable sensor technology
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.
Combined, these technologies form a hybrid closed loop system, which will deliver insulin based on real-time glucose data via an automated insulin delivery system, helping people living with type 1 diabetes improve how they manage their condition on a daily basis.
A hybrid closed loop system works by continuously monitoring a person’s glucose levels based on real-time readings from the glucose sensor with an algorithm in the app to calculate and deliver the right amount of insulin as needed. This removes the guesswork of insulin dosing and can improve health outcomes by helping people living with type 1 diabetes to improve their quality of life.
Draft guidance published by NICE in January recommended the use of hybrid closed loop systems, such as the one announced today by Abbott, for people with type 1 diabetes who require pump therapy.
Professor Partha S. Kar, OBE, National Specialty Advisor, Diabetes at NHS England said: “It is wonderful to see the coming together of Ypsomed’s mylife YpsoPump; CamAPX FX algorithm and Abbott’s FreeStyle Libre 3 sensor into one hybrid closed loop system – creating exciting opportunities for people living with type 1 diabetes. This type of advanced technology has the potential to change people’s lives for the better, so I’m pleased to see companies continue to innovate and bring functionality like this together, to allow for broader choice for patients and healthcare professionals.”
Hilary Nathan, Policy and Communications Director at Breakthrough T1D UK said: “The landscape for type 1 diabetes treatment is transforming with the use of technology and hybrid closed loop systems. We are in a dynamic period of progress, and we look forward to NICE approving hybrid closed loop later this spring in England and Wales. Underpinning all product and regulatory advances lies the central principle that patients have a range of choices to ensure evidence-based treatments fit the very personalised nature of type 1 diabetes.”
Neil Harris, General Manager of Abbott’s diabetes care business in the UK and Ireland said: “Our mission has always been to provide affordable and accessible technologies that help as many people as possible. We introduced FreeStyle Libre technology to Europe as the most affordable sensor, with the longest wear time on the market to help reduce some of the mental load that comes with managing the condition. This collaboration brings users of FreeStyle Libre 3 sensors in the UK a hybrid closed loop system that will allow them to spend even less time thinking about their diabetes and more time enjoying life.”
Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed, said: “We are convinced that the major challenges facing society can only be solved through partnerships. We are therefore proud to expand our offering with Abbott to give the users of our mylife™ YpsoPump more freedom of choice in managing their diabetes. Our compact and easy-to-use insulin pump authorised to work with Abbott’s latest sensor and CamDiab’s adaptive hybrid closed loop app will change the lives of thousands of people affected by diabetes.”
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s our mission to find cures and better treatments for type 1 and support everyone living with the condition. Can you donate today to help us?
